

MONOCLONAL ANTIBODY

Catalog No. CE-044A

Anti-Cytokeratin18 (CK18) antibody

BACKGROUND

Recently, it could be shown that the induction of CK 8/18 expression in non-malignant buccal mucosa cells resulted in a significant change of phenotypic characteristics after CK 8/18 transfection. These changes include an increased cellular motility, which might give first hints for an increased tumor aggressiveness and poor patient prognosis.

Product type	Primary antibodies
Host	Mouse
Source	Culture supernatant
Form	Liquid
	Purified monoclonal antibody in PBS, 50% Glycerol, 0.05% NaN3.
Volume	100 μl
Concentration	1 mg/ml
Specificity	Cytokeratin18
Antigen	Synthetic peptide corresponding to the C-terminal 10 aa (aa 414 $^{-}$ 423) of rat and mouse
	CK18, ETNDTRVLRH.
Clone	D2C7
Isotype	lgG2a

Application notes

WB, ICC, IHC Not tested for other applications.
Recommended dilutions
Western blotting, 1/1,000 to 1/5,000
Immunocytochemistry, 1/100 to 1/500
Immunohistochemistry, 1/100 to 1/500




Fig.1 Immunocytochemistry/ Immunofluorescence -Cytokeratin-18(CK18) antibody (D2C7) HeLa cells




Fig.2 Western blot - Cytokeratin-18(CK18) antibody (D2C7) 1.HeLa, 2.COS1, 3.rat liver, 4.mouse liver total extracts

Optimal dilutions/concentrations should be determined by the end user.

Cross reactivity Human, Monkey, Mouse, Rat Other species have not been tested.

Storage Store below -20°C (below -70°C for prolonged storag e).

References 1) Linder et al.,(2004) Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett.,214,1-9.

For research use only. Not for clinical diagnosis.

